PR Newswire Europe - Study Finds SEROQUEL Effective and Well Tolerated in Elderly Patients With Alzheimer’s Disease.
ALDERLEY PARK, England, March 4 /PRNewswire/ — AstraZeneca announced results from a study involving elderly patients with Alzheimer’s disease (AD) treated with the atypical antipsychotic SEROQUEL (quetiapine) today at the annual meeting of the American Association of Geriatric Psychiatry in San Diego, USA.
Related Results
New SeroquelSeroquel indicationSeroquel Backgrounder.Seroquel approvedAZ’s Seroquel faces competition
The study found that SEROQUEL at 200 mg/day was effective in reducing agitation in elderly patients with AD without leading to a decline in cognitive function. SEROQUEL was also generally well tolerated with no incidence of cerebrovascular adverse events during treatment, …
Read the rest of this article with a Free Trial at HighBeam Research.
